Related Experiment Video
Updated: Feb 18, 2026

Interactions with and Membrane Permeabilization of Brain Mitochondria by Amyloid Fibrils
Published on: September 28, 2019
Fructose-human serum albumin interaction undergoes numerous biophysical and biochemical changes before forming AGEs
Asif Zaman1, Zarina Arif1, Moinuddin1
1Department of Biochemistry, Faculty of Medicine, Aligarh Muslim University, Aligarh, India.
Abstract:
Fructose is a reducing and highly lipogenic sugar that has unique metabolic effects in the liver. Non-enzymatic fructosylation of proteins generates advanced glycation end products (AGEs). Human serum albumin (HSA) may undergo fructosylation vis-à-vis AGEs formation. High fructose consumption may lead to structurally altered and functionally compromised fructosylated-HSA-AGEs, which can cause damage to hepatocytes resulting in hepatic macro- and microvesicular steatosis. In this study, HSA was incubated with varying concentrations of fructose for 10days and the induced changes were studied. Fructosylated-HSA exhibited hyperchromicity, increased AGE-specific fluorescence, quenching of tryptophan fluorescence and increased melting temperature. Nε-[carboxymethyl]-lysine (CML), was detected by liquid chromatography mass spectrometry (LC-MS). Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) results showed decreased mobility in fructosylated-HSA. Perturbations in secondary and tertiary structure were revealed by fourier transform-infrared spectroscopy (FT-IR), supported by far- and near-UV circular dichroism (CD). Dynamic light scattering (DLS) and Matrix-Assisted Laser Desorption Ionization-Time of Flight (MALDI-TOF) mass spectrometry studies suggested increase in molecular mass of fructosylated-HSA. Amyloidogenic aggregates were confirmed from Congo red, Thioflavin T assay and Scanning electron microscope (SEM). These investigations confirmed the structural alterations in fructosylated-HSA and warrants further study to probe the role of fructosylated-HSA-AGEs in hepatopathy vis-à-vis fatty liver diseases.
Related Concept Videos
Factors Affecting Protein-Drug Binding: Patient-Related Factors
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Drug Distribution: Plasma Protein Binding
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
Drug Binding to Blood Components
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
Factors Affecting Protein-Drug Binding: Protein-Related Factors
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...

